Xeris Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Xeris Pharmaceuticals
XERS Stock  USD 6.82  0.09  1.30%   
Xeris Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Xeris Pharmaceuticals' valuation are provided below:
Gross Profit
225 M
Profit Margin
(0.06)
Market Capitalization
1.1 B
Enterprise Value Revenue
4.9289
Revenue
266.1 M
There are over one hundred nineteen available fundamental gauges for Xeris Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should confirm Xeris Pharmaceuticals' prevalent fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 305.7 M in 2026. Enterprise Value is likely to gain to about 458.6 M in 2026

Xeris Pharmaceuticals Total Revenue

245.21 Million

Check Xeris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xeris Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 6.4 M, Depreciation And Amortization of 15.2 M or Interest Expense of 40.1 M, as well as many indicators such as Price To Sales Ratio of 2.68, Dividend Yield of 0.0 or Days Sales Outstanding of 79.36. Xeris financial statements analysis is a perfect complement when working with Xeris Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Xeris Stock
Check out the analysis of Xeris Pharmaceuticals Correlation against competitors.
For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

Xeris Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets209.1 M371.5 M146.6 M
Slightly volatile
Other Current Liabilities92.9 M88.5 M31.3 M
Slightly volatile
Total Current Liabilities121.3 M115.5 M39.6 M
Slightly volatile
Other Liabilities35.3 M33.6 M13 M
Slightly volatile
Property Plant And Equipment Net34.1 M32.4 M9.5 M
Slightly volatile
Current Deferred Revenue78.2 M74.5 M32 M
Slightly volatile
Accounts Payable5.2 M2.6 M3.4 M
Slightly volatile
Cash59.6 M82.4 M48.4 M
Slightly volatile
Non Current Assets Total187.6 M178.7 M62.1 M
Slightly volatile
Cash And Short Term Investments86.4 M82.4 M62.9 M
Slightly volatile
Net Receivables48.8 M46.5 M14 M
Slightly volatile
Common Stock Total Equity7.2 K6.9 K3.4 K
Slightly volatile
Common Stock Shares Outstanding177.2 M168.8 M54.4 M
Slightly volatile
Liabilities And Stockholders Equity209.1 M371.5 M146.6 M
Slightly volatile
Non Current Liabilities Total304.6 M290.1 M126.1 M
Slightly volatile
Capital Surpluse448.1 M426.8 M188.5 M
Slightly volatile
Other Current Assets4.9 M8.6 M3.4 M
Slightly volatile
Total Liabilities425.9 M405.6 M165.7 M
Slightly volatile
Property Plant And Equipment Gross42.8 M40.8 M12.5 M
Slightly volatile
Preferred Stock Total Equity88.4 M112.6 M83.8 M
Slightly volatile
Total Current Assets125.1 M192.8 M90.6 M
Slightly volatile
Short Term Debt25.6 M24.4 M5.8 M
Slightly volatile
Common Stock18.1 K17.2 K6.3 K
Slightly volatile
Property Plant Equipment11.5 M10.9 M4.5 M
Slightly volatile
Inventory58.2 M55.4 M14.7 M
Slightly volatile
Net Working Capital87.5 M77.3 M63.2 M
Slightly volatile
Short and Long Term Debt Total327.8 M312.2 M112 M
Slightly volatile
Long Term Debt135.2 M249.6 M88.2 M
Slightly volatile
Long Term Debt Total65 M100.1 M55.6 M
Slightly volatile
Capital Stock10.5 K17.2 K6.5 K
Slightly volatile
Non Current Liabilities Other2.1 M2.3 M6.1 M
Slightly volatile
Deferred Long Term Liabilities3.9 M7.6 M2.9 M
Slightly volatile
Intangible Assets92.1 M89 M122.8 M
Slightly volatile
Short and Long Term Debt12.1 M13.6 M14.8 M
Slightly volatile

Xeris Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income6.4 M6.1 M1.9 M
Slightly volatile
Depreciation And Amortization15.2 M14.5 M4.4 M
Slightly volatile
Interest Expense40.1 M38.2 M10.4 M
Slightly volatile
Selling General Administrative197.4 M188 M67.8 M
Slightly volatile
Total Revenue245.2 M233.5 M60.1 M
Slightly volatile
Gross Profit200.7 M191.2 M48.9 M
Slightly volatile
Other Operating Expenses141.3 M272.2 M97.4 M
Slightly volatile
Research Development25.4 M23 M23.3 M
Slightly volatile
Cost Of Revenue44.5 M42.4 M11.3 M
Slightly volatile
Total Operating Expenses128.5 M229.9 M88 M
Slightly volatile
Reconciled Depreciation15.2 M14.5 M4.4 M
Slightly volatile

Xeris Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation22.2 M21.1 M6.9 M
Slightly volatile
Begin Period Cash Flow59.5 M82.4 M52.7 M
Slightly volatile
Depreciation15.2 M14.5 M4.3 M
Slightly volatile
Capital Expenditures1 M998.2 K630.1 K
Slightly volatile
End Period Cash Flow63.3 M87.1 M50.7 M
Slightly volatile
Change To Netincome15.3 M14.6 M6 M
Slightly volatile
Dividends Paid90.3 M169.1 M84 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.682.8226.2433
Slightly volatile
Days Sales Outstanding79.3683.54132
Pretty Stable
Stock Based Compensation To Revenue0.09880.10.4717
Pretty Stable
Capex To Depreciation0.07510.07910.7351
Very volatile
Inventory Turnover0.910.880.7897
Slightly volatile
Days Of Inventory On Hand359430467
Slightly volatile
Payables Turnover15.214.483.4129
Slightly volatile
Sales General And Administrative To Revenue4.667.716.1126
Slightly volatile
Research And Ddevelopement To Revenue0.140.12597.0933
Slightly volatile
Capex To Revenue0.00470.00490.0897
Very volatile
Cash Per Share0.530.569.589
Slightly volatile
Days Payables Outstanding24.7926.125.7 K
Slightly volatile
Income Quality1.020.781.0281
Slightly volatile
Intangibles To Total Assets0.470.430.4817
Slightly volatile
Current Ratio1.821.927.7964
Slightly volatile
Receivables Turnover3.915.786.2075
Slightly volatile
Capex Per Share0.00650.00680.0406
Pretty Stable
Revenue Per Share1.311.250.7185
Slightly volatile
Interest Debt Per Share1.271.871.0253
Slightly volatile
Debt To Assets0.430.760.4163
Slightly volatile
Operating Cycle406495334
Slightly volatile
Days Of Payables Outstanding24.7926.125.7 K
Slightly volatile
Ebt Per Ebit0.941.531.1158
Slightly volatile
Long Term Debt To Capitalization0.611.040.5487
Slightly volatile
Total Debt To Capitalization0.61.010.5444
Slightly volatile
Quick Ratio1.31.377.6259
Slightly volatile
Net Income Per E B T1.081.11.0031
Slightly volatile
Cash Ratio0.780.826.477
Slightly volatile
Days Of Inventory Outstanding359430467
Slightly volatile
Days Of Sales Outstanding79.3683.54132
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.920.9946
Slightly volatile
Fixed Asset Turnover3.736.484.2826
Slightly volatile
Debt Ratio0.430.760.4163
Slightly volatile
Price Sales Ratio2.682.8226.2433
Slightly volatile
Asset Turnover0.590.570.189
Slightly volatile
Gross Profit Margin0.870.940.8743
Slightly volatile

Xeris Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap305.7 M291.2 M149.2 M
Slightly volatile

Xeris Fundamental Market Drivers

Forward Price Earnings62.8931
Cash And Short Term Investments71.6 M

Xeris Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Xeris Pharmaceuticals Financial Statements

Xeris Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Xeris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Xeris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Xeris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue74.5 M78.2 M
Total Revenue233.5 M245.2 M
Cost Of Revenue42.4 M44.5 M
Stock Based Compensation To Revenue 0.10  0.10 
Sales General And Administrative To Revenue 7.71  4.66 
Research And Ddevelopement To Revenue 0.13  0.14 
Revenue Per Share 1.25  1.31 
Ebit Per Revenue(0.15)(0.16)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY